Rightway offers access to generic drugs offered by Cost Plus Drug through its mobile app.
Mark Cuban Cost Plus Drug Company has added Rightway to its network. The relationship grants members of Rightway’s PBM direct access to all medications available through Cost Plus Drug through its mobile app.
Scott Musial
“Cost Plus Drugs offers some of the lowest prices in the market,” Scott Musial, chief pharmacy officer of Rightway, said in a press release. “It enables Rightway to step away from the traditional supply chain, offering our members greater choice, lowering their spending, and giving them back time they’d spend at the pharmacy.”
Rightway calls itself a “care navigation” company that includes a PBM platform that members can access through a mobile app. The PBM provides pass-through pricing and personalized clinical management.
The company’s pharmacists will identify members, such as those with chronic conditions, who may benefit from the service with Cost Plus Drugs and help them transfer their medications if they choose to do so. Rightway’s health guides will assist any members interested in transferring their medications, from answering their questions to coordinating with healthcare providers.
Mark Cuban Cost Plus Drug Company launched in January 2022 to provide lower-cost generic medications. medications are priced at cost with a 15% markup The direct-to-consumer pharmacy now carries almost 1,000 medications.
Rightway also recently launched RightwayHub to streamline access to digital healthcare solutions. The program brings together a range of vetted programs across condition areas including musculoskeletal health, behavioral health, and chronic care management. The hub includes 10 solutions.
Get the latest industry news, event updates, and more from Managed healthcare Executive.
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 25th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
FDA Extends Review of Blenrep Combinations in Multiple Myeloma
July 24th 2025Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing and tolerability. The new action date is Oct. 23, 2025.
Read More
Sarepta to Pause Shipments of the Gene Therapy Elevidys
July 22nd 2025Sarepta officials said the temporary halt in shipments was done to maintain a productive working relationship with regulators while they address a safety labeling update about the risk of acute liver disease related to Elevidys.
Read More